14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PVLA vs SYRE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Palvella Therapeutics, Inc. (PVLA) on higher Unified Composite conviction (36.1/100 SELL vs. 48.2/100 HOLD) after splitting the core matrix 4–1 (led by Profitability & Quality), while PVLA wins 2–1 across the 6-pillar growth and valuation breakdown. PVLA trades at $145.03 (N/M Forward P/E, 0.0% operating margin) versus SYRE at $99.97 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (4–1 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PVLA vs SYRE. Trailing 12-month operating profitability (PVLA 0.0% vs SYRE 0.0%) and valuation multiples (PVLA N/M vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PVLA vs SYRE Key Questions & Quantitative Answers
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) captures the overall head-to-head institutional edge over Palvella Therapeutics, Inc. (PVLA) on higher Unified Composite conviction (36.1/100 SELL vs. 48.2/100 HOLD) after splitting the core matrix 4–1 (led by Profitability & Quality), while PVLA wins 2–1 across the 6-pillar growth and valuation breakdown. PVLA trades at $145.03 (N/M Forward P/E, 0.0% operating margin) versus SYRE at $99.97 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (4–1 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
PVLA and SYRE split Growth & Scale metrics: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PVLA generates N/A in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.
PVLA and SYRE trade at balanced relative valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus SYRE (-35.0% ROE) capital efficiency.
In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.